Pen or syringe? study tests easier way to take arthritis drug
NCT ID NCT06946524
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study tested how well the drug risankizumab (SKYRIZI) enters the body when given by a prefilled pen compared to a prefilled syringe. Fifty-nine healthy adults received a single injection, and researchers measured drug levels and side effects. The goal was to see if the pen delivers the drug as effectively as the syringe, which could make it easier for patients to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Risankizumab (brand name SKYRIZI)
What this could lead to
If the pen works as well as the syringe, patients may have a more convenient way to take this medication.
What could go wrong
This was a small, early-stage study in healthy volunteers, not patients. Results may not predict real-world use or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acpru /Id# 275116
Grayslake, Illinois, 60030, United States
-
Altasciences Clinical Los Angeles /ID# 276446
Cypress, California, 90630, United States